1. Pink Sheet
  2. >>Market Access

Colombian Crack Down On Compulsory Licensing Under Attack

 
• By Francesca Bruce

Civil society groups are calling for Colombian authorities to repeal a controversial decree that they say will make compulsory licensing harder and which would prevent declarations of public interest from being used to lower drug prices.

Colombia
Colombian NGOs Fight For Compulsory Licensing • Source: Shutterstock

Civil society groups in Colombia have signed a letter calling for the Colombian government to repeal a decree that they say stifles compulsory licensing and prevents declarations of interest (DPIs) from being used to control medicine prices. According to the groups, the decree, published by the ministry of commerce, is to punish the health ministry for slashing the price of Novartis AG‘s cancer drug Glivec (imatinib) after declaring it to be of public interest.

The ministry of commerce published decree 670 of 2017 in April. The decree changes the procedures for declaring the existence...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

EU’s Life Sciences Strategy Faces Race Against Time, Says Clinical Trials Community

 
• By Vibha Sharma

The report gave examples of missed opportunities for innovation and patient access, as well as regulatory and operational problems that undermine the conduct of timely clinical trials in Europe.

Quotable: Top Experts On Policy Hot Topics

 
• By Anabel Costa-Ferreira

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Leqembi Facing 15% Price Cut In Japan

 
• By Lisa Takagi

Japan looks set to press ahead with a reimbursement price cut for Eisai's Alzheimer's drug Leqembi following a cost-effectiveness review, despite differences with the company over methodology.